Jake Schauberger

Three Key Takeaways from the 2023 PERT Consortium

In the ever-evolving landscape of pulmonary embolism (PE) management, the PERT Consortium had established itself as a pivotal entity, significantly furthering the advancement of patient-centered care. This was vividly illustrated at the recent conference, which brought together a multidisciplinary team of experts, fostering a collaborative approach in both research and clinical practice, and paving the way for more comprehensive and nuanced care strategies.

Reflecting on the engaging sessions, we appreciated the rich discourse on recent developments in PE risk stratification, diagnostic algorithms and therapeutic modalities. The gathering served as a convergence of evidence-based insights and a platform to retrospectively analyze the ongoing trials and research setting new benchmarks in the field. Through focused learning and collaboration, we engaged in a fruitful exchange of ideas, enhancing our understanding and approach towards the management of PE.

Here are our three key takeaways from the Annual PERT Consortium:

1. Significant PE Clinical Data is on the Horizon

At the recent PERT Consortium meeting, a critical focus was placed on the diligent analysis of emerging prospective clinical studies, which are set to augment the existing corpus of evidence in the field of PE. Paramount among the discussions were findings and methodologies from seminal studies including APEX-AV, HI-PEITHO, PEERLESS, PE-TRACT, and STORM-PE. These investigations are fostering a deeper understanding of the pathophysiological dynamics of PE through rigorous clinical evaluations, meticulous data collection and nuanced analysis. 

A recurring theme was the potential role of Artificial Intelligence (AI) in leveraging the enriched datasets from these studies to augment diagnostic precision. However, it was acknowledged that the transition to AI-assisted diagnostics necessitates a careful and critical appraisal of the existing clinical evidence to ensure the development of algorithms that are both reliable and robust. The attendees underscored the necessity for AI tools to be grounded in high-quality clinical evidence, thus ensuring that such advancements are built upon a solid foundation of scientifically rigorous, peer-reviewed research. The consensus emphasized a cautious yet optimistic approach, recognizing the potential of AI in enhancing diagnostic procedures, while also underscoring the imperative of meticulous, evidence-based progression in this burgeoning field of medicine.

2. AI is making a demonstrable impact on clinical outcomes

The meeting also shed light on the progressive role of AI in the refinement of Pulmonary Embolism Response Teams (PERTs). Utilizing AI’s data analysis capabilities, PERTs can now facilitate quicker, more precise diagnostic processes, which is pivotal in the context of PE, where timely intervention can significantly influence outcomes. Furthermore, AI assists in the personalization of treatment strategies by helping analyze a myriad of variables quickly, thus potentially improving patient outcomes through tailored approaches. Aidoc has demonstrated statistically significant reductions in ICU Length of Stay and time to treatment decision (Cedars 2022) at previous PERT Annual meetings. This year, Aidoc AI broke three more abstracts, adding to the corpus of 35+ peer-reviewed PE-related papers, abstracts, or posters validating Aidoc software. This year, additional evidence was released that corroborated significant multi-day reductions in Length of Stay, sensitivity of the clinical AI algorithm in predicting PERT activations compared to the standard of care and the performance of the automated risk stratification RV/LV ratio algorithm.

3. Management of PE is highly variable, across disparate systems.

Managing pulmonary embolisms (PEs) is complex due to the heterogeneous nature of patient presentations, the multifaceted pathophysiological underpinnings of the condition and the necessity for a rapid yet nuanced approach to diagnosis and treatment, which often involves the coordination of a multidisciplinary team of specialists. This complexity highlights the value of the operational enhancements made possible on Aidoc’s Clinical AI platform. Currently integrated with critical systems such as Electronic Medical Records, scheduling utilities, and enterprise imaging databases, the platform stands as a transformative tool in the PE care landscape. It offers a cohesive solution that streamlines both clinical and administrative workflows, facilitating real-time communication and collaborative decision-making amongst various specialists. 

By centralizing operations in a unified system, it ensures a smoother transition between different care environments, providing a consolidated view of patient data that is essential in handling the diverse presentations of PE patients. Furthermore, it accommodates logistical operations, including efficient scheduling management in both inpatient and outpatient settings, thus reducing administrative burdens and promoting a focused approach to patient care. 

In this way, Aidoc’s platform not only aids in diagnostic procedures but also fosters administrative excellence, marking a substantial step in advancing toward a data-driven and efficient PE patient management system.

Jake Schauberger